{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:44:02Z","timestamp":1746701042158},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00120-020-01323-5","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T09:03:54Z","timestamp":1600247034000},"page":"1265-1274","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urothelkarzinom des oberen Harntrakts"],"prefix":"10.1007","volume":"59","author":[{"given":"A. J.","family":"Gross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Netsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-U.","family":"Stolzenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","volume":"189","author":"DA Green","year":"2013","unstructured":"Green\u00a0DA, Rink\u00a0M, Xylinas\u00a0E et\u00a0al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J\u00a0Urol 189:1214\u20131221. https:\/\/doi.org\/10.1016\/j.juro.2012.05.079","journal-title":"J Urol"},{"key":"1323_CR2","unstructured":"Leitlinienprogramm Onkologie (2020) Leitlinie Harnblasenkarzinom. https:\/\/www.Leitlinienprogramm-onkologie.de\/Harnblasenkarzinom.92.0.html. Zugegriffen: 17. Apr. 2020"},{"key":"1323_CR3","unstructured":"https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Harnblasenkrebs\/harnblasenkrebs_node.html;jsessionid=CF04A84E695E86EC256A07367250AF35.2_cid372. Zugegriffen: 03.09.2020"},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria\u00a0F, Shariat\u00a0SF, Lerner\u00a0SP et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379\u2013387. https:\/\/doi.org\/10.1007\/s00345-016-1928-x","journal-title":"World J Urol"},{"key":"1323_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","volume":"31","author":"M Cosentino","year":"2013","unstructured":"Cosentino\u00a0M, Palou\u00a0J, Gaya\u00a0JM et\u00a0al (2013) Upper urinary tract urothelial cell carcinoma: location as a\u00a0predictive factor for concomitant bladder carcinoma. World J Urol 31:141\u2013145. https:\/\/doi.org\/10.1007\/s00345-012-0877-2","journal-title":"World J Urol"},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2011.07.010","volume":"60","author":"RJM Lammers","year":"2011","unstructured":"Lammers\u00a0RJM, Witjes\u00a0WPJ, Hendricksen\u00a0K et al (2011) Smoking status is a\u00a0risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 60:713\u2013720. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.010","journal-title":"Eur Urol"},{"key":"1323_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","volume":"65","author":"JJ Crivelli","year":"2014","unstructured":"Crivelli\u00a0JJ, Xylinas\u00a0E, Kluth\u00a0LA et\u00a0al (2014) Effect of smoking on outcomes of urothelial carcinoma: a\u00a0systematic review of the literature. Eur Urol 65:742\u2013754. https:\/\/doi.org\/10.1016\/j.eururo.2013.06.010","journal-title":"Eur Urol"},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200326010-00004","volume":"26","author":"J-P Cosyns","year":"2003","unstructured":"Cosyns\u00a0J\u2011P (2003) Aristolochic acid and \u201cChinese herbs nephropathy\u201d: a\u00a0review of the evidence to date. Drug Saf 26:33\u201348. https:\/\/doi.org\/10.2165\/00002018-200326010-00004","journal-title":"Drug Saf"},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","volume":"42","author":"JY Ju","year":"2018","unstructured":"Ju\u00a0JY, Mills\u00a0AM, Mahadevan\u00a0MS et\u00a0al (2018) Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas. Am J Surg Pathol 42:1549\u20131555. https:\/\/doi.org\/10.1097\/PAS.0000000000001141","journal-title":"Am J Surg Pathol"},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.juro.2010.12.093","volume":"185","author":"H Jung","year":"2011","unstructured":"Jung\u00a0H, Gleason\u00a0JM, Loo\u00a0RK et\u00a0al (2011) Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J\u00a0Urol 185:1698\u20131703. https:\/\/doi.org\/10.1016\/j.juro.2010.12.093","journal-title":"J Urol"},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","volume":"38","author":"F Janisch","year":"2020","unstructured":"Janisch\u00a0F, Shariat\u00a0SF, Baltzer\u00a0P et al (2020) Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a\u00a0systematic review and meta-analysis. World J Urol 38:1165\u20131175. https:\/\/doi.org\/10.1007\/s00345-019-02875-8","journal-title":"World J Urol"},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","volume":"183","author":"N Takahashi","year":"2010","unstructured":"Takahashi\u00a0N, Glockner\u00a0JF, Hartman\u00a0RP et\u00a0al (2010) Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J\u00a0Urol 183:1330\u20131365. https:\/\/doi.org\/10.1016\/j.juro.2009.12.031","journal-title":"J Urol"},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00345-019-02732-8","volume":"37","author":"G Fojecki","year":"2019","unstructured":"Fojecki\u00a0G, Magnusson\u00a0A, Traxer\u00a0O et\u00a0al (2019) Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma. World J Urol 37:2271\u20132278. https:\/\/doi.org\/10.1007\/s00345-019-02732-8","journal-title":"World J Urol"},{"key":"1323_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","volume":"108","author":"J Messer","year":"2011","unstructured":"Messer\u00a0J, Shariat\u00a0SF, Brien\u00a0JC et al (2011) Urinary cytology has a\u00a0poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701\u2013705. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09899.x","journal-title":"BJU Int"},{"key":"1323_CR15","doi-asserted-by":"publisher","first-page":"e13859","DOI":"10.1097\/MD.0000000000013859","volume":"97","author":"H Jin","year":"2018","unstructured":"Jin\u00a0H, Lin\u00a0T, Hao\u00a0J et al (2018) A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Medicine 97:e13859. https:\/\/doi.org\/10.1097\/MD.0000000000013859","journal-title":"Medicine"},{"key":"1323_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ajcp\/aqy170","volume":"151","author":"N Sassa","year":"2019","unstructured":"Sassa\u00a0N, Iwata\u00a0H, Kato\u00a0M et\u00a0al (2019) Diagnostic utility of UroVysion combined with conventional urinary cytology for urothelial carcinoma of the upper urinary tract. Am J Clin Pathol 151:469\u2013478. https:\/\/doi.org\/10.1093\/ajcp\/aqy170","journal-title":"Am J Clin Pathol"},{"key":"1323_CR17","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bju.14053","volume":"121","author":"R-Q Guo","year":"2018","unstructured":"Guo\u00a0R\u2011Q, Hong\u00a0P, Xiong\u00a0G\u2011Y et al (2018) Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a\u00a0meta-analysis. BJU Int 121:184\u2013193. https:\/\/doi.org\/10.1111\/bju.14053","journal-title":"BJU Int"},{"key":"1323_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/bju.13935","volume":"120","author":"M Marchioni","year":"2017","unstructured":"Marchioni\u00a0M, Primiceri\u00a0G, Cindolo\u00a0L et al (2017) Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a\u00a0systematic review and meta-analysis. BJU Int 120:313\u2013319. https:\/\/doi.org\/10.1111\/bju.13935","journal-title":"BJU Int"},{"key":"1323_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12894-015-0068-8","volume":"15","author":"S Golan","year":"2015","unstructured":"Golan\u00a0S, Nadu\u00a0A, Lifshitz\u00a0D (2015) The role of diagnostic ureteroscopy in the era of computed tomography urography. BMC Urol 15:74. https:\/\/doi.org\/10.1186\/s12894-015-0068-8","journal-title":"BMC Urol"},{"key":"1323_CR20","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/PAS.0b013e3181aec42a","volume":"33","author":"F Tavora","year":"2009","unstructured":"Tavora\u00a0F, Fajardo\u00a0DA, Lee\u00a0TK et\u00a0al (2009) Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol 33:1540\u20131546. https:\/\/doi.org\/10.1097\/PAS.0b013e3181aec42a","journal-title":"Am J Surg Pathol"},{"key":"1323_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.urology.2016.04.030","volume":"96","author":"AM Potretzke","year":"2016","unstructured":"Potretzke\u00a0AM, Knight\u00a0BA, Vetter\u00a0JM et al (2016) Diagnostic utility of selective upper tract urinary cytology: a systematic review and meta-analysis of the literature. Urology 96:35\u201343. https:\/\/doi.org\/10.1016\/j.urology.2016.04.030","journal-title":"Urology"},{"key":"1323_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.euf.2017.05.008","volume":"4","author":"A Breda","year":"2018","unstructured":"Breda\u00a0A, Territo\u00a0A, Guttilla\u00a0A et\u00a0al (2018) Correlation between confocal laser endomicroscopy (Cellvizio\u00ae) and histological grading of upper tract urothelial carcinoma: a step forward for a\u00a0better selection of patients suitable for conservative management. Eur Urol Focus 4:954\u2013959. https:\/\/doi.org\/10.1016\/j.euf.2017.05.008","journal-title":"Eur Urol Focus"},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.aju.2017.01.003","volume":"15","author":"E Osman","year":"2017","unstructured":"Osman\u00a0E, Alnaib\u00a0Z, Kumar\u00a0N (2017) Photodynamic diagnosis in upper urinary tract urothelial carcinoma: a systematic review. Arab J Urol 15:100\u2013109. https:\/\/doi.org\/10.1016\/j.aju.2017.01.003","journal-title":"Arab J Urol"},{"key":"1323_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11934-018-0833-9","volume":"19","author":"S Pearce","year":"2018","unstructured":"Pearce\u00a0S, Daneshmand\u00a0S (2018) Enhanced endoscopy in bladder cancer. Curr Urol Rep 19:84. https:\/\/doi.org\/10.1007\/s11934-018-0833-9","journal-title":"Curr Urol Rep"},{"key":"1323_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/end.2019.0725","volume":"34","author":"T Yoshida","year":"2020","unstructured":"Yoshida\u00a0T, Setsuda\u00a0S, Ishizuka\u00a0M et al (2020) Photodynamic diagnosis with oral 5\u2011aminolevulinic acid for upper urinary tract carcinoma: a prospective clinical trial. J\u00a0Endourol 34:509\u2013515. https:\/\/doi.org\/10.1089\/end.2019.0725","journal-title":"J Endourol"},{"key":"1323_CR26","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.eururo.2009.12.001","volume":"57","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani\u00a0G, Sun\u00a0M, Perrotte\u00a0P et al (2010) Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. Eur Urol 57:956\u2013962. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.001","journal-title":"Eur Urol"},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-016-1819-1","volume":"35","author":"G Gakis","year":"2017","unstructured":"Gakis\u00a0G, Schubert\u00a0T, Alemozaffar\u00a0M et al (2017) Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol 35:327\u2013335. https:\/\/doi.org\/10.1007\/s00345-016-1819-1","journal-title":"World J Urol"},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.juro.2012.12.006","volume":"189","author":"ML Cutress","year":"2013","unstructured":"Cutress\u00a0ML, Stewart\u00a0GD, Tudor\u00a0ECG et al (2013) Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. J\u00a0Urol 189:2054\u20132060. https:\/\/doi.org\/10.1016\/j.juro.2012.12.006","journal-title":"J Urol"},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","volume":"70","author":"T Seisen","year":"2016","unstructured":"Seisen\u00a0T, Peyronnet\u00a0B, Dominguez-Escrig\u00a0JL et al (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 70:1052\u20131068. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.014","journal-title":"Eur Urol"},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.acuro.2020.02.003","volume":"44","author":"JA Campos-Sa\u00f1udo","year":"2020","unstructured":"Campos-Sa\u00f1udo\u00a0JA, Ballestero-Diego\u00a0R, Zubillaga-Guerrero\u00a0S et al (2020) Impact of radical nephrectomy on kidney function and prognostic factors for adverse cardiovascular events. Actas Urol Esp 44:239\u2013244. https:\/\/doi.org\/10.1016\/j.acuro.2020.02.003","journal-title":"Actas Urol Esp"},{"key":"1323_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat\u00a0M, Babjuk\u00a0M, Comp\u00e9rat\u00a0E et\u00a0al (2018) European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"1323_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11934-016-0595-1","volume":"17","author":"JD Raman","year":"2016","unstructured":"Raman\u00a0JD, Jafri\u00a0SM (2016) Complications following radical nephroureterectomy. Curr Urol Rep 17:36. https:\/\/doi.org\/10.1007\/s11934-016-0595-1","journal-title":"Curr Urol Rep"},{"key":"1323_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00104-006-1186-3","volume":"77","author":"C Langer","year":"2006","unstructured":"Langer\u00a0C, Becker\u00a0H (2006) Treatment of abdominal wall defects, including abdominal relaxation. Chirurg 77:414\u2013423. https:\/\/doi.org\/10.1007\/s00104-006-1186-3","journal-title":"Chirurg"},{"key":"1323_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jso.25840","volume":"121","author":"G Rosiello","year":"2020","unstructured":"Rosiello\u00a0G, Palumbo\u00a0C, Deuker\u00a0M et al (2020) Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. J\u00a0Surg Oncol 121:688\u2013696. https:\/\/doi.org\/10.1002\/jso.25840","journal-title":"J Surg Oncol"},{"key":"1323_CR35","doi-asserted-by":"publisher","first-page":"290.e17","DOI":"10.1016\/j.urolonc.2018.12.027","volume":"37","author":"S Zeng","year":"2019","unstructured":"Zeng\u00a0S, Dai\u00a0L, Yang\u00a0J et\u00a0al (2019) Development and external validation of a\u00a0nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol 37:290.e17\u2013290.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2018.12.027","journal-title":"Urol Oncol"},{"key":"1323_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/lps.1991.1.343","volume":"1","author":"RV Clayman","year":"1991","unstructured":"Clayman\u00a0RV, Kavoussi\u00a0LR, Figenshau\u00a0RS et\u00a0al (1991) Laparoscopic nephroureterectomy: initial clinical case report. J\u00a0Laparoendosc Surg 1:343\u2013349. https:\/\/doi.org\/10.1089\/lps.1991.1.343","journal-title":"J Laparoendosc Surg"},{"key":"1323_CR37","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.eururo.2012.02.019","volume":"61","author":"S Ni","year":"2012","unstructured":"Ni\u00a0S, Tao\u00a0W, Chen\u00a0Q et\u00a0al (2012) Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a\u00a0systematic review and cumulative analysis of comparative studies. Eur Urol 61:1142\u20131153. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.019","journal-title":"Eur Urol"},{"key":"1323_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/end.2017.0086","volume":"31","author":"JF Rodriguez","year":"2017","unstructured":"Rodriguez\u00a0JF, Packiam\u00a0VT, Boysen\u00a0WR et\u00a0al (2017) Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J\u00a0Endourol 31:661\u2013665. https:\/\/doi.org\/10.1089\/end.2017.0086","journal-title":"J Endourol"},{"key":"1323_CR39","doi-asserted-by":"publisher","first-page":"e602","DOI":"10.1016\/j.clgc.2019.03.003","volume":"17","author":"S Nazzani","year":"2019","unstructured":"Nazzani\u00a0S, Preisser\u00a0F, Mazzone\u00a0E et\u00a0al (2019) Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 17:e602\u2013e611. https:\/\/doi.org\/10.1016\/j.clgc.2019.03.003","journal-title":"Clin Genitourin Cancer"},{"key":"1323_CR40","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","volume":"172","author":"J Palou","year":"2004","unstructured":"Palou\u00a0J, Piovesan\u00a0LF, Huguet\u00a0J et al (2004) Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J\u00a0Urol 172:66\u201369. https:\/\/doi.org\/10.1097\/01.ju.0000132128.79974.db","journal-title":"J Urol"},{"key":"1323_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.urology.2018.05.042","volume":"121","author":"KB Scotland","year":"2018","unstructured":"Scotland\u00a0KB, Kleinmann\u00a0N, Cason\u00a0D et al (2018) Ureteroscopic management of large \u22652\u202fcm upper tract urothelial carcinoma: a comprehensive 23-year experience. Urology 121:66\u201373. https:\/\/doi.org\/10.1016\/j.urology.2018.05.042","journal-title":"Urology"},{"key":"1323_CR42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1089\/end.2019.0308","volume":"33","author":"L Defidio","year":"2019","unstructured":"Defidio\u00a0L, Antonucci\u00a0M, De Dominicis\u00a0M et al (2019) Thulium-holmium:YAG duo laser in conservative upper tract urothelial cancer treatment: 13 years experience from a\u00a0tertiary national referral center. J\u00a0Endourol 33:902\u2013908. https:\/\/doi.org\/10.1089\/end.2019.0308","journal-title":"J Endourol"},{"key":"1323_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/end.2016.0611","volume":"31","author":"S Yoo","year":"2017","unstructured":"Yoo\u00a0S, You\u00a0D, Song\u00a0C et\u00a0al (2017) Risk of intravesical recurrence after ureteroscopic biopsy for upper tract urothelial carcinoma: Does the location matter? J\u00a0Endourol 31:259\u2013265. https:\/\/doi.org\/10.1089\/end.2016.0611","journal-title":"J Endourol"},{"key":"1323_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11934-017-0675-x","volume":"18","author":"DP Verges","year":"2017","unstructured":"Verges\u00a0DP, Lallas\u00a0CD, Hubosky\u00a0SG, Bagley\u00a0DH (2017) Endoscopic treatment of upper tract urothelial carcinoma. Curr Urol Rep 18:31. https:\/\/doi.org\/10.1007\/s11934-017-0675-x","journal-title":"Curr Urol Rep"},{"key":"1323_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12894-019-0482-4","volume":"19","author":"G-L Huang","year":"2019","unstructured":"Huang\u00a0G\u2011L, Luo\u00a0H\u2011L, Chiang\u00a0P\u2011H (2019) Does preoperative percutaneous nephrostomy insertion worsen upper-tract urothelial cancer oncological outcome? A retrospective single center study. BMC Urol 19:50. https:\/\/doi.org\/10.1186\/s12894-019-0482-4","journal-title":"BMC Urol"},{"key":"1323_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/14737140.2017.1326823","volume":"17","author":"JD Raman","year":"2017","unstructured":"Raman\u00a0JD, Park\u00a0R (2017) Endoscopic management of upper-tract urothelial carcinoma. Expert Rev Anticancer Ther 17:545\u2013554. https:\/\/doi.org\/10.1080\/14737140.2017.1326823","journal-title":"Expert Rev Anticancer Ther"},{"key":"1323_CR47","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/cncr.25050","volume":"116","author":"SF Matin","year":"2010","unstructured":"Matin\u00a0SF, Margulis\u00a0V, Kamat\u00a0A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127\u20133134. https:\/\/doi.org\/10.1002\/cncr.25050","journal-title":"Cancer"},{"key":"1323_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","volume":"200","author":"RS Liao","year":"2018","unstructured":"Liao\u00a0RS, Gupta\u00a0M, Schwen\u00a0ZR et\u00a0al (2018) Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J\u00a0Urol 200:68\u201373. https:\/\/doi.org\/10.1016\/j.juro.2017.12.054","journal-title":"J Urol"},{"key":"1323_CR49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow\u00a0JJ, Martin-Doyle\u00a0W, Fay\u00a0AP et al (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.003","journal-title":"Eur Urol"},{"key":"1323_CR50","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","volume":"35","author":"T Seisen","year":"2017","unstructured":"Seisen\u00a0T, Krasnow\u00a0RE, Bellmunt\u00a0J et\u00a0al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma. J\u00a0Clin Oncol 35:852\u2013860. https:\/\/doi.org\/10.1200\/JCO.2016.69.4141","journal-title":"J Clin Oncol"},{"key":"1323_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi\u00a0A, Lo Vullo\u00a0S, Mariani\u00a0L et al (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a\u00a0joint study by the European Association of Urology-Young Academic Urologists and the\u00a0Upper Tract Urothelial Carcinoma Collaboration. BJU Int 121:252\u2013259. https:\/\/doi.org\/10.1111\/bju.14020","journal-title":"BJU Int"},{"key":"1323_CR52","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle\u00a0A, Johnson\u00a0M, Chester\u00a0J et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a\u00a0phase 3, open-label, randomised controlled trial. Lancet 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet"},{"key":"1323_CR53","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Castellano\u00a0D, O\u2019Donnell\u00a0PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a\u00a0multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","journal-title":"Lancet Oncol"},{"key":"1323_CR54","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a\u00a0single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet"},{"key":"1323_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrurol.2015.24","volume":"12","author":"T Seisen","year":"2015","unstructured":"Seisen\u00a0T, Colin\u00a0P, Roupr\u00eat\u00a0M (2015) Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 12:155\u2013166. https:\/\/doi.org\/10.1038\/nrurol.2015.24","journal-title":"Nat Rev Urol"},{"key":"1323_CR56","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","volume":"65","author":"E Xylinas","year":"2014","unstructured":"Xylinas\u00a0E, Kluth\u00a0L, Passoni\u00a0N et al (2014) Prediction of intravesical recurrence after radical nephroureterectomy: development of a\u00a0clinical decision-making tool. Eur Urol 65:650\u2013658. https:\/\/doi.org\/10.1016\/j.eururo.2013.09.003","journal-title":"Eur Urol"},{"key":"1323_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1046\/j.1442-2042.2001.00286.x","volume":"8","author":"N Sakamoto","year":"2001","unstructured":"Sakamoto\u00a0N, Naito\u00a0S, Kumazawa\u00a0J et\u00a0al (2001) Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a\u00a0prospective randomized study. Int J Urol 8:212\u2013216. https:\/\/doi.org\/10.1046\/j.1442-2042.2001.00286.x","journal-title":"Int J Urol"},{"key":"1323_CR58","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000350508","volume":"91","author":"D Fang","year":"2013","unstructured":"Fang\u00a0D, Li\u00a0X\u2011S, Xiong\u00a0G\u2011Y et al (2013) Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a\u00a0systematic review and meta-analysis. Urol Int 91:291\u2013296. https:\/\/doi.org\/10.1159\/000350508","journal-title":"Urol Int"},{"key":"1323_CR59","unstructured":"Roupr\u00eat M et al (2020) Upper urinary tract urothelial cell carcinoma. 8. Follow-up. https:\/\/uroweb.org\/guideline\/upper-urinary-tract-urothelial-cell-carcinoma\/#8. Zugegriffen:  03.09.2020"},{"key":"1323_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.urology.2009.10.004","volume":"75","author":"C Jeldres","year":"2010","unstructured":"Jeldres\u00a0C, Sun\u00a0M, Isbarn\u00a0H et al (2010) A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 75:315\u2013320. https:\/\/doi.org\/10.1016\/j.urology.2009.10.004","journal-title":"Urology"},{"key":"1323_CR61","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1016\/j.ejca.2009.06.016","volume":"45","author":"G Lughezzani","year":"2009","unstructured":"Lughezzani\u00a0G, Jeldres\u00a0C, Isbarn\u00a0H et al (2009) Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a\u00a0population-based study of 2299 patients. Eur J Cancer 45:3291\u20133297. https:\/\/doi.org\/10.1016\/j.ejca.2009.06.016","journal-title":"Eur J Cancer"},{"key":"1323_CR62","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.juro.2012.10.057","volume":"189","author":"M Roupr\u00eat","year":"2013","unstructured":"Roupr\u00eat\u00a0M, Hupertan\u00a0V, Seisen\u00a0T et\u00a0al (2013) Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J\u00a0Urol 189:1662\u20131669. https:\/\/doi.org\/10.1016\/j.juro.2012.10.057","journal-title":"J Urol"},{"key":"1323_CR63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/end.2015.0248","volume":"30","author":"P Motamedinia","year":"2016","unstructured":"Motamedinia\u00a0P, Keheila\u00a0M, Leavitt\u00a0DA et al (2016) The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J\u00a0Endourol 30:262\u2013267. https:\/\/doi.org\/10.1089\/end.2015.0248","journal-title":"J Endourol"},{"key":"1323_CR64","doi-asserted-by":"publisher","DOI":"10.23736\/S0393-2249.20.03689-9","author":"G Bozzini","year":"2020","unstructured":"Bozzini\u00a0G, Gastaldi\u00a0C, Besana\u00a0U et al (2020) Thulium-laser Retrograde Intra Renal Ablation (T-RIRA) of upper urinary tract transitional cell carcinoma: an ESUT study. Minerva Urol Nefrol. https:\/\/doi.org\/10.23736\/S0393-2249.20.03689-9","journal-title":"Minerva Urol Nefrol"},{"key":"1323_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10040201","author":"C-S Chen","year":"2020","unstructured":"Chen\u00a0C\u2011S, Li\u00a0J\u2011R, Wang\u00a0S\u2011S et al (2020) Tumor multifocality is a\u00a0significant risk factor of urinary bladder recurrence after nephroureterectomy in patients with upper tract urothelial carcinoma: a single-institutional study. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics10040201","journal-title":"Diagnostics"},{"key":"1323_CR66","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12894-019-0557-2","volume":"19","author":"S Li","year":"2019","unstructured":"Li\u00a0S, Pan\u00a0Y, Hu\u00a0J (2019) Oncologic outcomes comparison of partial ureterectomy and radical nephroureterectomy for urothelial carcinoma. BMC Urol 19:120. https:\/\/doi.org\/10.1186\/s12894-019-0557-2","journal-title":"BMC Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01323-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-020-01323-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01323-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T23:25:34Z","timestamp":1631748334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-020-01323-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01323-5","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"16 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>A.\u00a0Gross<\/b>: A.\u00a0Finanzielle Interessen: A.\u00a0Gross gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt f\u00fcr Urologie, Asklepios Klinik Barmbek\u00a0|\u00a0Mitgliedschaften: Vereinigung Norddeutscher Urologen (Pr\u00e4sident), Kongresspr\u00e4sident Weltkongress f\u00fcr Endourologie. <b>C.\u00a0Netsch<\/b>: A.\u00a0Finanzielle Interessen: Finanzielle Unterst\u00fctzung bei Studien: Boston Scientific. \u2013 Honorar, Kostenerstattung: Richard Wolf\u00a0|\u00a0Kostenerstattung: Karl Storz. \u2013 Berater: Richard Wolf. \u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Asklepios Klinik Barmbek, Abteilung f\u00fcr Urologie\u00a0|\u00a0Mitgliedschaften: AK Endourologie (DGU), ESUT (EAU), Endourological Society. <b>J.-U.\u00a0Stolzenburg<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Deutsche Krebshilfe e.\u202fV. \u2013 Vortragshonorare, Erstattung von Kongressgeb\u00fchren, Reise- und Hotelkosten: Janssen, Intuitive, Olympus. \u2013 Aktieninhaber: avateramedical N.V. \u2013 B.\u00a0Nichtfinanzielle Interessen: Lehrstuhlinhaber, Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum Leipzig\u00a0|\u00a0Niedergelassener Urologe\u00a0|\u00a0Mitgliedschaften: Deutschen Gesellschaft f\u00fcr Urologie e.\u202fV., S\u00e4chsische Gesellschaft f\u00fcr Urologie, EAU. <b>B.\u00a0Becker<\/b>: A.\u00a0Finanzielle Interessen: B.\u00a0Becker gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Assistenzarzt f\u00fcr Urologie, Asklepios Klinik Barmbek, Hamburg.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}